Survivorship in AML – a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years. Issue 13 (9th November 2020)

• Record Type: Journal Article
• Authors: Major, Catherine Kendall; Kantarjian, Hagop; Sasaki, Koji; Borthakur, Gautam; Kadia, Tapan; Pemmaraju, Naveen; DiNardo, Courtney; Short, Nicholas J.; Daver, Naval; Jabbour, Elias; Champlin, Richard; Garcia-Manero, Guillermo; Konopleva, Marina; Andreeff, Michael; Kornblau, Steven; Wierda, William; Pierce, Sherry; Ravandi, Farhad; Cortes, Jorge
• Is Part Of: Leukemia & lymphoma. Volume 61:Issue 13(2020)
• Page Start: 3120
• Page End: 3127
• Publication Date: 2020-11-09
• Subjects: Acute myeloid leukemia -- survivorship -- remission -- comorbidities; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2020.1802450
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: Acute myeloid leukemia (AML) carries poor survival and high recurrence rate. We conducted a retrospective analysis of AML patients ( N = 453) treated with chemotherapy only or chemotherapy + hematopoietic cell transplant (HCT) who maintained their first complete remission (CR) for ≥3 years. Prior comorbidities, new comorbidities, secondary malignancies, late relapse, and causes of death (COD) were documented. New comorbidities for chemotherapy only patients ( n = 304) included renal disease (10%), and osteopenia/osteoporosis (38%) for HCT patients ( n = 149). Incidence of hypertension was similar in the chemotherapy only cohort and chemotherapy + HCT cohort (14% vs 17%). Secondary malignancies occurred in 13%, commonly skin, prostate and breast cancers. Common COD included: secondary malignancy (4%), HCT complications (3%), and late relapses (5%). Overall, 12% had a late relapse. Median overall survival for chemotherapy only and HCT was 10.7 and 12.7 years, respectively. Long-term AML survivors need routine monitoring for comorbidities, secondary malignancies, and late relapses.